Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Champions Oncology (CSBR) over the last 5 years, with Q4 2025 value amounting to $97000.0.

  • Champions Oncology's Other Accumulated Expenses fell 3576.16% to $97000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $97000.0, marking a year-over-year decrease of 3576.16%. This contributed to the annual value of $135000.0 for FY2025, which is 1000.0% down from last year.
  • According to the latest figures from Q4 2025, Champions Oncology's Other Accumulated Expenses is $97000.0, which was down 3576.16% from $116000.0 recorded in Q3 2025.
  • Champions Oncology's Other Accumulated Expenses' 5-year high stood at $154000.0 during Q1 2025, with a 5-year trough of $15000.0 in Q3 2021.
  • In the last 5 years, Champions Oncology's Other Accumulated Expenses had a median value of $143500.0 in 2022 and averaged $116000.0.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 86000.0% in 2023, then tumbled by 3576.16% in 2025.
  • Champions Oncology's Other Accumulated Expenses (Quarter) stood at $15000.0 in 2021, then skyrocketed by 853.33% to $143000.0 in 2022, then rose by 3.5% to $148000.0 in 2023, then rose by 2.03% to $151000.0 in 2024, then crashed by 35.76% to $97000.0 in 2025.
  • Its Other Accumulated Expenses was $97000.0 in Q4 2025, compared to $116000.0 in Q3 2025 and $135000.0 in Q2 2025.